9:00am - 5:00pm

Our Opening Hours Mon. - Fri.

1.800.799.2234

Call Us For Free Consultation

Facebook

Twitter

Search
 

Gemcitabine and Epirubicin in Treating Patients With Malignant Mesothelioma

Top West Virginia Mesothelioma Lawyer | Law Firm | Attorney | GPW > Gemcitabine and Epirubicin in Treating Patients With Malignant Mesothelioma

Gemcitabine and Epirubicin in Treating Patients With Malignant Mesothelioma

Estimated reading time: < 1 min

Condition: Malignant Mesothelioma

Estimated Enrollment: 69

Gender: All

Min Age: 18 Years

Age Group: Adult, Older Adult

Current Status: Completed

Study Results: No Results Available

Outcome Measures: time to progression,  survival,  quality of life,

Interventions: epirubicin hydrochloride, gemcitabine hydrochloride

Phase:

Study Type: Interventional

Study Design: Intervention Model: Single Group Assignment, Masking: None (Open Label), Primary Purpose: Treatment,

Primary Completion Date: August 2004

Completion Date: May 2008

Last  Posted Date: December 7, 2016

Location: MBCCOP – Gulf Coast, Mobile, Alabama, United States

Website Link: https://ClinicalTrials.gov/show/NCT00017186

Was this article helpful?
Dislike 0